Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of the E. coli–derived 9-valent HPV vaccine in Chinese men aged 18-45 years
CTR20250669Phase 3Active
- Sponsor
- Xiamen Wantai Canghai Biotechnology Co., Ltd.
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in human papillomavirus infection, anogenital warts, penile cancer, anal cancer, sponsored by Xiamen Wantai Canghai Biotechnology Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
human papillomavirus infectionanogenital wartspenile canceranal cancer
Beyond the preview
Go deeper on CTR20250669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250669.